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Chemokine receptor antagonists are set to become novel important 
pharmacological tools within the current therapeutic repertoire available for 
the management of various inflammatory conditions. 
Currently in various phases of drug development, these 
molecules act by inhibiting specific inflammatory pathways, 
and current research suggests a safer adverse effect profile 
for these drugs than today's therapy. I 
Introduction 
Chemokines represent a large family of proteins that are 
produced by a variety of cells, including stromal cells, 
epithelial cells and immune cells. They are cell activators 
and chemoattractants, regulating the traffic of cells through 
a chemotactic gradient. They have a pivotal role in the 
trafficking ofa variety ofleukocytes such as T-lymphocytes 
and neutrophils and endothelial cells: (a) within primary 
lymphoid organs, (b) from primary to secondary lymphoid 
organs, (c) between secondary lymphoid organs, and (d) 
during a humoral immune response.2 They therefore posses 
an essential role in both the inflammatory and immunological 
processes. 
Classification 
Over forty human chemokines have been currently 
iuentifieu (Table 1), anu these have been dassified by 
structure into four sub-classes, according to the number and 
spacing of conserved cysteine residues in the chemotactic 
domain. These four sub-classes are given the preferred 
names C, CC, CXC and CXXXC, with CC possessing two 
cysteine residues adjacent to each other, CXC and CXXXC 
possessing one and three amino acids respectively between 
the cysteine residues and the C having one of the two 
r.ystf.im~ rf.SiOllf.S missing (Figlln~ I) 
Chemokine Former designation Receptor(s) 
CCL3 MIP-la CCRl, CCR5 
CCL5 RANTES CCRl, CCR3, CCR5 
CCL8 MCP-2 CCRl, CCR2, CCR3 
CCLl7 TARC CCR4 
CXCLl2 SDF-l, PBSF CXCR4 
Table 1: Some chemokine ligands and their ~pecific receptors 
MIP-1a : Macrophage inflammatory protein 1 alpha, 
RANTES: Regulated upon Activation, Normal T-cell 
Expressed, and Secreted, MCP-2: Macrophage 
chemoattractant protein 2, TARC: Thymus and activation-
regulated chemokine, SDF-1: stromal cell-derived factor-
1, PBSF: pre-B cell growth-stimulating factor. 
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Figure 1: The common structure and chromosomal location 
of the four chemokine sub-classes, showing the location of 
cysteine residues, after which they are named All chemokines 
have at least three ~-pleated sheets (indicated as ~1-3) and 
a C-terminal a -helix. The CX3C chemokine domain occurs 
at the end of a long stalk which is heavily substituted with 
mucin-like carbohydrates. The protein is embedded in the 
membrane and has a short cytoplasmic domain. 
(Reproducedfrom Rollins, 1997. 22) 
Chemokine receptors 
Chemokine receptors are structurally and functionally 
related proteins, that are members of the class A G-protein 
coupled receptors (GPCRs); they are all coupled to Ginhibitory 
proteins. 3 
Currently 18 proteins that meet the definition for a 
chemokine receptor exist, with each sub-family of the 
chemokine class of inflammatory mediators having its own 
sub-class of receptors. Of these 18 known proteins, 10 are 
known to be CCRs, 6 are CXCRs, and only one receptor is 
known for each of the CXXXC and C sub-classes 
(CXXXCRl and XCRl respectively). 
Of all of these receptors, it is of interest to note that only the 
CXCR4 has been found to be essential for life.4 
continues on page 14 
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Figure 2: Chemokine receptor activation. (Gia-~y: G-protein, GDP: Guanosine diphosphate, GTP: Guanosine- triphosphate. 
Adapted from O'Hayre et ai, 2008.23 ) 
continued from page 4 
Chemokine receptors are commonly 
known to exhibit promiscuity,s that is, 
while certain chemokines show a 
preference for their own specific receptor; 
they may also interact with other receptors, 
causing activation. With the same idea, 
receptors themselves may also be activated 
by other, non-specific chemokines. This 
is known as the shared receptor concept, 
which occurs within, but not between the 
CC or CXC branches, except for the Du:ffY 
antigen/receptor for chemokine (DARC) 
which binds to the CC and CXC classes 
with equal affinity.6 An example of this 
concept is the chemokine ligand MIP -1 a 
which binds with high affinity to CCRl, 
CCR3 and CCR5. 
Mode of action 
Chemokines act by regulating leukocyte 
recruitment; causing cellular activation 
and inflammatory mediator release by 
promoting the Th2 inflammatory response 
and by regulating the release ofIgE. Their 
immunomodulatory and chemoattractant 
action occurs via the infiltration of 
inflammatory cells and by the 
inflammatory burst caused from 
eosinophils and basophils. This causes 
the migration ofleukocytes, a critical 
component of systemic immunity, from 
the vascular compartment into the tissues 
through a process of chemotaxis. This 
highlights the importance of chemokines 
as inflammatory mediators as well as the 
significance of their receptors, the 
regulation of expression of which is 
recognised as one ofthe key events in 
leukocyte localisation and trafficking 
during inflammation. Indeed, chemokine 
expression has been reported to play a 
major role in (a) glomerulonephritis, (b) 
inflammatory bowel disease, (c) allergenic 
transplant rejection, (d) atopic dennatitis, 
(e) allergic rhinitis, (t) asthma, and (g) 
chronic obstructive puhnonary disease.7 
This list further includes auto-immune 
disease such as diabetes and multiple 
sclerosis, stemming from the fact that 
chemokines are also able to direct immune 
cells to target and destroy perfectly healthy 
cells. 
Therefore antagonism of various 
chemokine receptors has been proposed 
as a useful therapeutic approach in the 
management of inflammatory conditions, 
and indeed several such molecules are 
currently under development as novel 
therapeutic agents. 8 
Chemokine receptor antagonists 
The shared receptor concept may make 
it more beneficial for the pharmaceutical 
industry to design and produce receptor 
antagonists, rather than drugs that 
antagonise the chemokine ligands directly. 
Indeed various chemokine receptor 
antagonists are currently being developed 
as novel therapeutic tools for a variety of 
diseases. For example, CCR4 antagonists 
are currently under development for 
asthma therapeutics. High levels of the 
CCR4ligands RANTES, MCP-l , TARC 
and MDC have been detected in both the 
sputum and serum of asthmatics.9 
Antagonism ofthe CCR4, a receptor that 
has been determined to be a selective 
marker for Jh2 type lymphocytes,5. 10 has 
been shown to result in decreased 
eosinophilia and diminished airway 
hyperresponsivness. II ,12 
It has been recently demonstrated that 
CCR4 antagonism may be used as a 
mechanism to inhibit the recruitment of 
activated leukocytes. 13 These CCR4 
antagonists' include the neutralising 
antibody IG 1, which has been shown to 
potentially block TARC binding to CCR4 
transfectants and to prevent chemotaxis 
of these cells in response to MDC and 
TARC.7 Also under development are 
spironolactams and spiroperidines,3 a 
series of2-aminothiazole derivatives 
aimed at inhibiting TARC and MDC 
binding to the CCR4,14 as well as 2,4-
diaminoquinazolines, whose 
administration in a murine model of acute 
dermatitis showed significant anti-
inflammatory activity. IS 
Other antagonists include the pyrazolone 
methylamino piperidine derivatives and 
the patented product GW-766994, both 
CCR3 antagonists, the latter of which is 
currently undergoing Phase IT clinical 
trials for the treatment of asthma and 
allergic rhinitis. Besides having CCR4 
antagonistic activity, the spiroperidines 
(llso exert (l very potent CCR? hlo~king 
action,16 while the CCRl antagonist 
BX471 has been reported to be efficient 
in a rat heterotrophic heart transplant 
rej ection model. 17 
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